Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs
Reuters reported that Novo Nordisk launched Wegovy in India in June 2025, and the lower doses were priced around 17,345 per month , with higher monthly costs for stronger doses
Example Colesevelam (Welchol) Dosage Initial: 3,750 mg daily, either in one dose or divided into two doses (available as pills or packets of powder) Maximum: 3,750 mg in one or two doses Bromocriptine-QR [Cycloset] (a dopamine agonist) Primary mechanism(s) of action Acts on the central nervous system, particularly the hypothalamus, as a dopamine D2 receptor agonist, increasing insulin sensitivity in liver, muscle, and fat (adipose tissue) Dosage Initial: 0.8 mg once daily, within two hours of waking Maximum: 4.8 mg daily Possible side effects include: Nausea and vomiting (usually improves with continued use) Low blood pressure (hypotension) Injectable (Non-Insulin) Type 2 Diabetes Drugs There are three classes of injectable drugs approved to treat type 2 diabetes
Injectable glutathione bypasses the digestive system, where oral glutathione undergoes significant breakdown by stomach acid and intestinal enzymes